Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to provide written, informed consent and to be compliant with the schedule of protocol assessments~2. Positive skin prick or in vitro reactivity test to ≥ 1 perennial aeroallergen~3. Total serum IgE level of ≥30 to ≤700 IU/ml.~4. Moderate to Severe persistent asthma requiring regular treatment with high dose of inhaled corticosteroid (ICS) (GINA 2019 step 4 treatment).~5. Body weight of ≥30 to ≤150~6. History of one of these 2 items during the past 12 months:~   * At least 2 asthma exacerbations which needed systemic corticosteroids, (≥30 days prior to screening)~  * Severe asthma exacerbation in which peak expiratory flow (PEF) or FEV1 was less than 60% of the patient best result and needed systemic corticosteroids and hospitalization or emergency department visit, (≥30 days prior to screening)~Exclusion Criteria:~1. Smoking history of ≥10 pack-years~2. Chronic use of corticosteroids (use of 20 to 30 mg prednisolone for more than 3 weeks) or other immunosuppressant due to other disease except asthma such as autoimmune or collagen vascular disease and etc.~3. Treatment with omalizumab in the 12 months before screening~4. History of severe allergic or anaphylactic reactions to Omalizumab~5. Active lung disease other than asthma~6. Acute upper respiratory tract infection within 1 month before screening~7. Unable to perform spirometry test and other tests needed in the trial~8. Female subjects who are not willing to practice effective contraception (as defined by the investigator) during the study~9. Nursing mothers, pregnant women, and women who planned to become pregnant while on study~10. Participation in any other investigational study within 6 months prior to randomization~11. Unwillingness or inability to comply with the requirements of the protocol including the presence of any condition (physical, mental, or social) that was likely to affect the subject's ability to comply with the study protocol~12. Persons have an asthma exacerbation requiring intubation in the 12 months before screening~13. Unexpected events that prevent patient entering the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab (CinnaGen) (Type: EXPERIMENTAL): Omalizumab (CinnaGen) was administered every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg/IgE for a duration of 28 weeks
- Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) (Type: ACTIVE_COMPARATOR): Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg/IgE for a duration of 28 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).